Literature DB >> 7014069

Septicemia in childhood malignancy. Analysis of 101 consecutive episodes.

J S Miser, A W Miser, W A Bleyer, R L Chard.   

Abstract

One hundred one consecutive episodes of blood-culture-positive infection were evaluated in 83 children with malignancy between 1972 and 1977. Eighty-two per cent occurred in relapse, and 75% developed when the absolute neutrophil count was less than 500 per microliters. Forty per cent were fatal. Forty-five per cent of the episodes occurring in relapse and 17% occurring in remission were fatal. Of 88 cases of single-organism infection, 46% were due to gram-positive organisms with a 13% mortality (of these, 28% were due to Staphylococcus aureus with a 4% mortality); 52% were due to gram-negative organisms with a 52% mortality; and two episodes were due to fungal organisms with no fatalities. Multiple-organism infection occurred 13 times, of which 11 episodes were fatal. The authors' data confirm observations by others that the organisms most commonly causing blood-culture-positive infection in children with malignancy are S. aureus and Escherichia coli and that infection due to gram-positive organisms, particularly S. aureus, is less than frequency fatal.

Entities:  

Mesh:

Year:  1981        PMID: 7014069     DOI: 10.1177/000992288102000502

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  3 in total

1.  Serum immunoglobulins to endotoxin core glycolipid: acute leukaemia and other cancers.

Authors:  S K Jackson; J Parton; G Shortland; J M Stark; E N Thompson
Journal:  Arch Dis Child       Date:  1990-07       Impact factor: 3.791

2.  [Septicemia in leukemia and malignant lymphoma. Incidence pathogens--causes].

Authors:  H H Hennemann
Journal:  Klin Wochenschr       Date:  1985-09-02

3.  Comparative in vitro study of temocillin (BRL 17421), a new penicillin.

Authors:  R Bolivar; S S Weaver; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.